Dapagliflozin 5 mg & Metformin 1000 mg Prolonged-release Tablets
Dapagliflozin 5 mg & Metformin 1000 mg Prolonged-release Tablets — Antidiabetics & Metabolism, as prolonged-release tablets, available for private-label manufacture from 10,000 units, produced in India. Below, the active substance of this Antidiabetics & Metabolism product appears under its International Nonproprietary Name, with the strength per unit that the specification gives.
| Dosage form | Prolonged-release tablets |
|---|---|
| Pack | 2 x 15 tablets in Alu-Alu blisters; bulk packs on request |
| Minimum order | 10,000 units |
| Manufactured in | India |
| Registration | Not yet registered in Iraq — product open for exclusive registration in your name |
| Market status | Choose your market: Iraq · Gulf · EuropeIraq: the registration status is in the row above.Gulf: on offer for the Gulf states. The Gulf pageEurope: on offer for European buyers. Details |
| Documents | Certificate of Analysis, Certificate of Origin, Certificate of Conformity, Free Sale Certificate and MSDS — available on request. |
| Products Library | Open this formulation's card (F1960) |
About this formulation
This formulation, Dapagliflozin 5 mg & Metformin 1000 mg Prolonged-release Tablets, belongs to the Antidiabetics & Metabolism range; it is made in India for private-label brands from 10,000 units per SKU. Our production site is not yet registered in Iraq, so the product is open for registration in your name. The production time is set in our offer for this product. Declared actives include Dapagliflozin 5 mg and Metformin hydrochloride 1000 mg.
The Antidiabetics & Metabolism range: The modern oral diabetes shelf, gliptins and gliflozins, alone and with metformin.
Related formulations
Active ingredients
- Dapagliflozin 5 mg per prolonged-release tablet
- Metformin hydrochloride 1000 mg per prolonged-release tablet
Prolonged-release tablets with 5 mg dapagliflozin and 1000 mg metformin hydrochloride each, an oral combination of an SGLT2 inhibitor and a biguanide; prescription medicine for use under medical direction; 2 x 15 tablets in blisters.
Market status in detail
Iraq. Our production site for this line has no Iraqi file yet. The site registration comes first; the product is then filed in your name; for a medicine, with a new CPP. How filing works in Iraq
Gulf. This product is on offer for the Gulf states. Tell us the country and the quantity, and we answer with the offer and the documents we supply.
Country pages: Saudi Arabia · UAE · Kuwait · Qatar · Oman · Bahrain
Europe. This product is on offer for European buyers. Tell us the country and the quantity, and we answer with the offer and the documents we supply.
Change market: Iraq · Gulf · Europe · All markets
Shipping and document legalisation for your country are calculated separately and stated in the offer.